Basecamp Wealth Advisors’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.94M Sell
7,722
-2
-0% -$430 0.36% 31
2026
Q1
$1.68M Sell
7,724
-16
-0.2% -$3.55K 0.35% 29
2025
Q4
$1.77M Buy
+7,740
New +$1.76M 0.38% 26

Other funds holding ABBV

Basecamp Wealth Advisors's ABBV Position: Q2 2026 in Review

Basecamp Wealth Advisors reduced its AbbVie (ABBV) stake by 0.03% in Q2 2026, selling an estimated $430 and leaving 7,722 shares worth $1.94M. The position accounts for 0.36% of the portfolio, ranked #31.

Basecamp Wealth Advisors first reported a position in ABBV in Q4 2025 and has held it in 3 quarters since. 4,180 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Basecamp Wealth Advisors held 7,722 shares of AbbVie worth $1.94M as of Q2 2026.
  • Basecamp Wealth Advisors sold 2 AbbVie shares in Q2 2026, an estimated $430.
  • AbbVie made up 0.36% of Basecamp Wealth Advisors's portfolio in Q2 2026, its #31 holding.
  • Basecamp Wealth Advisors first reported a position in AbbVie in Q4 2025 and has held it in 3 quarters since.
  • 4,180 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.